All News

Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.

Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are.

i1-715251-1408620005477.jpg

Pharmaceutical Executive

Focus Reports discusses kep questions regarding France's pharma industry

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

A new study indicates that doctors are no longer switching offices - largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.

Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.

i1-679208-1408630541252.jpg

Pharmaceutical Executive

A heavily rigid agency network structure that fights against their strategic objectives is the last thing clients should be looking for.

i1-679207-1408630542928.jpg

Pharmaceutical Executive

An ideal partner is one that will work with manufacturers on a variable cost basis, providing the ability to scale resources up and down as new products are introduced and marketing and sales needs change.

i1-679221-1408630520062.jpg

Pharmaceutical Executive

To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.

i1-679224-1408630514644.jpg

Pharmaceutical Executive

Sure, there might be a few key audiences whose view of your reputation is critical, but targeting them is fairly simple and often inexpensive. More times than not, it's better to keep your head down than raise the banner and lead the field.

i1-679215-1408630530827.jpg

Jamie Peck, Rosetta

Pharmaceutical Executive

Independence equals creativity, and solutions

i1-679217-1408630528062.jpg

Pharmaceutical Executive

The monolithic dictates out of marketing and agency headquarters in New York and London-and the way they are forced on local marketing efforts-work to undermine adoption at the local level

i1-679213-1408630533961.jpg

Jon Hussey, Palio

Pharmaceutical Executive

In China people view expenditures on pharmaceuticals as a "cost" rather than a "purchase"

i1-679216-1408630529462.jpg

Pharmaceutical Executive

The pharma industry has only recently seen the kinds of price pressures that the retail industry has operated under for decades.

Pharmaceutical Executive

The companies with the best corporate reputations have responsibility initiatives that earn their way, but very few of them started in response to a perceived problem or a bit of bad press.

i1-676061-1408632840440.jpg

Pharmaceutical Executive

Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"